Skip to reading

Consultation desk

Questioning claims about a protein fragment

Start desk

Quick brief

Understand · The essentials

# The short answer, with room to breathe.

If you have little time or a busy mind, begin here. These are the answers to hold onto before you read further.

A path for your questions

Keep the essentials

Name your concern

Bring a question

A brief can be a starting point. Open the detail when you need it.

## Keep the essentials

### No approval. No published human study.

As of September 2026, no TB-500 medicine is approved in the US.

The FDA, short for Food and Drug Administration, found no published human study of TB-500 in its checked review.

The unknown effects are a gap in the evidence, not proof that nothing can go wrong.

Chapter notes

The FDA review behind this brief

FDA’s approval data

## What that means for a visit

### Ask about the concern first.

You can arrive at a visit without having chosen a treatment. Explain your concern and what you want to learn from the visit.

Ask which care options fit the problem.

Ask for the evidence behind each option.

Ask what the visit costs even if no medicine is offered.

Ask who will answer questions after the visit.

A question to carry

## What supports using this for my problem?

For TB-500, FDA found no published study in people as of the September 2026 check.

If the answer points to thymosin beta-4 research, ask why a finding for a different substance is being used.

Chapter notes

FDA’s distinction between the substances

Back a desk What it is

Next learning step US rules

Use these desks to sort out care questions; this guide shares information, offers no clinic care and sells no medicines.

All desks

Word help

Read as text

Start

Care

Costs

Cautions

Words